- Home
- ABUS vs ERII Comparison
ABUS vs ERII Comparison
Compare ABUS & ERII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- ERII
- Stock Information
- Founded
- ABUS 2005
- ERII 1992
- Country
- ABUS United States
- ERII United States
- Employees
- ABUS N/A
- ERII N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- ERII Industrial Machinery/Components
- Sector
- ABUS Health Care
- ERII Technology
- Exchange
- ABUS Nasdaq
- ERII Nasdaq
- Market Cap
- ABUS 711.2M
- ERII 801.2M
- IPO Year
- ABUS N/A
- ERII 2008
- Fundamental
- Price
- ABUS $4.38
- ERII $15.77
- Analyst Decision
- ABUS Strong Buy
- ERII Buy
- Analyst Count
- ABUS 2
- ERII 4
- Target Price
- ABUS $5.00
- ERII $18.75
- AVG Volume (30 Days)
- ABUS 1.4M
- ERII 468.1K
- Earning Date
- ABUS 11-05-2025
- ERII 10-29-2025
- Dividend Yield
- ABUS N/A
- ERII N/A
- EPS Growth
- ABUS N/A
- ERII 25.10
- EPS
- ABUS N/A
- ERII 0.43
- Revenue
- ABUS $15,416,000.00
- ERII $141,775,000.00
- Revenue This Year
- ABUS $138.02
- ERII $6.16
- Revenue Next Year
- ABUS N/A
- ERII $13.06
- P/E Ratio
- ABUS N/A
- ERII $36.53
- Revenue Growth
- ABUS 53.23
- ERII 6.19
- 52 Week Low
- ABUS $2.71
- ERII $10.86
- 52 Week High
- ABUS $5.10
- ERII $20.27
- Technical
- Relative Strength Index (RSI)
- ABUS 54.52
- ERII 68.03
- Support Level
- ABUS $4.25
- ERII $15.22
- Resistance Level
- ABUS $4.66
- ERII $15.47
- Average True Range (ATR)
- ABUS 0.17
- ERII 0.42
- MACD
- ABUS -0.03
- ERII 0.07
- Stochastic Oscillator
- ABUS 41.67
- ERII 71.19
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About ERII Energy Recovery Inc.
Energy Recovery Inc is an engineering-driven technology company. It is engaged in engineering, designing, manufacturing and supplying solutions that make industrial processes more efficient and sustainable. The company operates in three segments, Water, Emerging Technologies and Corporate. It offers energy recovery devices (ERDs) and pumps as well as related products and services to the reverse osmosis desalination market. The company derives a majority of the revenue from the Water segment. Geographically, the company operates in the U.S. and other international countries.